Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/17571
Title: LncRNA JHDM1D-AS1 Is a key biomarker for progression and modulation of gemcitabine sensitivity in bladder cancer cells.
Authors: Pereira, Isadora Oliveira Ansaloni
Silva, Glenda Nicioli da
Almeida, Tamires Cunha
Lima, Ana Paula Braga
Sávio, André Luiz Ventura
Leite, Katia Ramos Moreira
Salvadori, Daisy Maria Fávero
Keywords: Bladder cancer
Long non-coding RNAs
Issue Date: 2023
Citation: PEREIRA, I. O. A. et al. LncRNA JHDM1D-AS1 Is a key biomarker for progression and modulation of gemcitabine sensitivity in bladder cancer cells. Molecules, v. 28, artigo 2412, 2023. Disponível em: <https://www.mdpi.com/1420-3049/28/5/2412>. Acesso em: 01 ago. 2023.
Abstract: Long non-coding RNAs are frequently found to be dysregulated and are linked to carcinogenesis, aggressiveness, and chemoresistance in a variety of tumors. As expression levels of the JHDM1D gene and lncRNA JHDM1D-AS1 are altered in bladder tumors, we sought to use their combined expression to distinguish between low-and high-grade bladder tumors by RTq-PCR. In addition, we evaluated the functional role of JHDM1D-AS1 and its association with the modulation of gemcitabine sensitivity in high-grade bladder-tumor cells. J82 and UM-UC-3 cells were treated with siRNA-JHDM1D-AS1 and/or three concentrations of gemcitabine (0.39, 0.78, and 1.56 µM), and then submitted to cytotoxicity testing (XTT), clonogenic survival, cell cycle progression, cell morphology, and cell migration assays. When JHDM1D and JHDM1D-AS1 expression levels were used in combination, our findings indicated favorable prognostic value. Furthermore, the combined treatment resulted in greater cytotoxicity, a decrease in clone formation, G0/G1 cell cycle arrest, morphological alterations, and a reduction in cell migration capacity in both lineages compared to the treatments alone. Thus, silencing of JHDM1D-AS1 reduced the growth and proliferation of high-grade bladder-tumor cells and increased their sensitivity to gemcitabine treatment. In addition, the expression of JHDM1D/JHDM1D-AS1 indicated potential prognostic value in the progression of bladder tumors.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/17571
metadata.dc.identifier.doi: https://doi.org/10.3390/molecules28052412
ISSN: 1420-3049
metadata.dc.rights.license: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_LncRNAJHDM1D.pdf3,29 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.